|
WO2020100969A1
|
|
Pharmaceutical composition for treating diffuse-type gastric cancer
|
|
WO2019230595A1
|
|
Treatment agent for diffuse gastric cancer
|
|
JP2020089608A
|
|
Seal marker and method for identifying lesion region of lung
|
|
EP3539382A1
|
|
Antibacterial member
|
|
JP2018162974A
|
|
Hematopoietic organ tumor therapeutic agent, and screening method
|
|
JP2017176074A
|
|
Antisense oligonucleic acid compounds and sequencing methods thereof
|
|
JP2017085911A
|
|
In vivo degradable proteins and methods for in vivo degradation of proteins
|
|
JP2017063614A
|
|
Method for screening substance that suppresses or inhibits abnormal macromolecularization of caspase-3
|
|
JP2017035395A
|
|
Design method of heart supporter, manufacturing method of heart supporter, and heart supporter
|
|
JP2016096988A
|
|
Body height measurement method, body height measurement apparatus, and body height measurement program
|
|
JP2016040542A
|
|
Screening method of therapeutic agent for dementia or candidate substance of therapeutic agent for dementia
|
|
JP2015050998A
|
|
Culture vessel
|
|
JP2015211771A
|
|
Vertical puncture support system
|
|
JP2016135100A
|
|
Erythroblast enucleation method, and enucleated erythrocyte maintenance method
|
|
JP2014214126A
|
|
Therapeutic agent for pancreatic cancer
|
|
JP2014166234A
|
|
Cardiac configuration correction net fitting device
|
|
JP2014166235A
|
|
Construction method and program for three-dimensional model of organ
|
|
EP2772278A1
|
|
Light exposure device for improving cognitive symptoms and depression symptoms
|
|
JP2013183995A
|
|
Method for manufacturing heart correction net
|
|
JP2013183994A
|
|
Heart correction net
|
